Search

Your search keyword '"Wechalekar A"' showing total 37 results
Start Over Author "Wechalekar A" Publication Type Electronic Resources
37 results on '"Wechalekar A"'

1. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C, Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A, Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, Kastritis, Efstathios, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Jaccard, Arnaud, Bridoux, Frank, Roeloffzen, Wilfried, Minnema, Monique C, Bergantim, Rui, Hájek, Roman, João, Cristina, Cibeira, M Teresa, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Dimopoulos, Meletios A, Ravichandran, Sriram, Hegenbart, Ute, Agis, Hermine, Gros, Blanca, Asra, Aisha, Magarotto, Valeria, Cheliotis, Giorgos, Psarros, Giorgos, Sonneveld, Pieter, Wechalekar, Ashutosh, and Kastritis, Efstathios

Published
2024

2. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Author

Hong, Lih En, Wechalekar, Mihir D., Kutyna, Monika, Small, Annabelle, Lim, Kelly, Thompson-Peach, Chloe, Li, Joule J., Chhetri, Rakchha, Scott, Hamish S., Brown, Anna, Hahn, Christopher N., Yeung, David T., Sajid, Salvia, Robinson, Nirmal, Thomas, Ranjeny, Branford, Susan, D'Andrea, Richard J., Samaraweera, Saumya E., Patnaik, Mrinal, Proudman, Susanna, Thomas, Daniel, Kok, Chung Hoow, Shah, Mithun V., Hiwase, Devendra K., Hong, Lih En, Wechalekar, Mihir D., Kutyna, Monika, Small, Annabelle, Lim, Kelly, Thompson-Peach, Chloe, Li, Joule J., Chhetri, Rakchha, Scott, Hamish S., Brown, Anna, Hahn, Christopher N., Yeung, David T., Sajid, Salvia, Robinson, Nirmal, Thomas, Ranjeny, Branford, Susan, D'Andrea, Richard J., Samaraweera, Saumya E., Patnaik, Mrinal, Proudman, Susanna, Thomas, Daniel, Kok, Chung Hoow, Shah, Mithun V., and Hiwase, Devendra K.

Abstract

High prevalence of IDH mutations in seronegative rheumatoid arthritis (RA) with myeloid neoplasm, elevated 2-hydroxyglutarate, dysregulated innate immunity, and proinflammatory microenvironment suggests causative association between IDH mutations and seronegative RA. Our findings merit investigation of IDH inhibitors as therapeutics for seronegative IDH-mutated RA.

Published
2024

4. The management of light chain (AL) amyloidosis in Europe:clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Author

Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Jaccard, Arnaud, Bridoux, Frank, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Roeloffzen, Wilfried, Cibeira, M. Teresa, Agis, Hermine, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Leonidakis, Alexandros, Cheliotis, Giorgos, Sonneveld, Pieter, Kastritis, Efstathios, Wechalekar, Ashutosh, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Jaccard, Arnaud, Bridoux, Frank, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Roeloffzen, Wilfried, Cibeira, M. Teresa, Agis, Hermine, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Leonidakis, Alexandros, Cheliotis, Giorgos, Sonneveld, Pieter, Kastritis, Efstathios, and Wechalekar, Ashutosh

Abstract

Systemic light-chain (AL) amyloidosis is a rare and debilitating disease. Advances have been made in new treatments in recent years, yet real-world data on the management of the disease are scarce. EMN23 is a retrospective, observational study of patients who initiated first-line treatment in 2004–2018 in Europe, presenting the demographics, clinical characteristics, treatment patterns, and outcomes, from 4480 patients. Regimens based on bortezomib were the most frequently used as first-line therapy; only 6.2% of the patients received autologous stem cell transplant. Hematologic responses improved post-2010 (67.1% vs 55.6% pre-2010). The median overall survival (OS) was 48.8 (45.2–51.7) months; 51.4 (47.3–57.7) months pre-2010 and 46.7 (41.3–52.2) months post-2010. Early mortality was 13.4% and did not improve (11.4% vs 14.4% pre- and post-2010); furthermore, it remained high in patients with advanced cardiac disease (over 39% for stage IIIb). There was a significant improvement for stage IIIa (14.2 vs 30.7 months, p = 0.0170) but no improvement for stage IIIb patients (5.0 vs 4.5 months). This European real-world study of AL-amyloidosis emphasizes the unmet needs of early diagnosis, and the lack of improvement in survival outcomes of the frail stage IIIb population, despite the introduction of new therapies in recent years.

Published
2023

5. The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Jaccard, Arnaud, Bridoux, Frank, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Roeloffzen, Wilfried, Cibeira, M. Teresa, Agis, Hermine, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Leonidakis, Alexandros, Cheliotis, Giorgos, Sonneveld, Pieter, Kastritis, Efstathios, Wechalekar, Ashutosh, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Palladini, Giovanni, Schönland, Stefan, Merlini, Giampaolo, Milani, Paolo, Jaccard, Arnaud, Bridoux, Frank, Dimopoulos, Meletios A., Ravichandran, Sriram, Hegenbart, Ute, Roeloffzen, Wilfried, Cibeira, M. Teresa, Agis, Hermine, Minnema, Monique C., Bergantim, Rui, Hájek, Roman, João, Cristina, Leonidakis, Alexandros, Cheliotis, Giorgos, Sonneveld, Pieter, Kastritis, Efstathios, and Wechalekar, Ashutosh

Published
2023

6. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: patient outcomes and impact of bendamustine dosing

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Arulogun, Suzanne O, Brian, Duncan, Goradia, Harshita, Cooney, Aaron, Menne, Tobias, Koo, RayMun, O'Neill, Aideen T, Vos, Josephine M I, Pratt, Guy, Turner, Deborah, Marshall, Kirsty, Manos, Kate, Anderson, Claire, Gavriatopoulou, Maria, Kyriakou, Charalampia, Kersten, Marie J, Minnema, Monique C, Koutoumanou, Eirini, El-Sharkawi, Dima, Linton, Kim, Talaulikar, Dipti, McCarthy, Helen, Bishton, Mark, Follows, George, Wechalekar, Ashutosh, D'Sa, Shirley P, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Arulogun, Suzanne O, Brian, Duncan, Goradia, Harshita, Cooney, Aaron, Menne, Tobias, Koo, RayMun, O'Neill, Aideen T, Vos, Josephine M I, Pratt, Guy, Turner, Deborah, Marshall, Kirsty, Manos, Kate, Anderson, Claire, Gavriatopoulou, Maria, Kyriakou, Charalampia, Kersten, Marie J, Minnema, Monique C, Koutoumanou, Eirini, El-Sharkawi, Dima, Linton, Kim, Talaulikar, Dipti, McCarthy, Helen, Bishton, Mark, Follows, George, Wechalekar, Ashutosh, and D'Sa, Shirley P

Published
2023

7. Predictors of outcome in a contemporary cardiac sarcoidosis population: Role of brain natriuretic peptide, left ventricular function and myocardial inflammation

Author

Kouranos, Vasileios; https://orcid.org/0000-0002-2723-0928, Khattar, Rajdeep S, Okafor, Joseph, Ahmed, Raheel, Azzu, Alessia, Baksi, John Arun, Wechalekar, Kshama, Cowie, Martin R, Wells, Athol Umfrey, Lüscher, Thomas F; https://orcid.org/0000-0002-5259-538X, Sharma, Rakesh, Kouranos, Vasileios; https://orcid.org/0000-0002-2723-0928, Khattar, Rajdeep S, Okafor, Joseph, Ahmed, Raheel, Azzu, Alessia, Baksi, John Arun, Wechalekar, Kshama, Cowie, Martin R, Wells, Athol Umfrey, Lüscher, Thomas F; https://orcid.org/0000-0002-5259-538X, and Sharma, Rakesh

Abstract

Aims Cardiac sarcoidosis (CS) is a potentially fatal condition that varies in its clinical presentation. Here, we describe baseline characteristics at presentation along with prognosis and predictors of outcome in a sizable and deeply phenotyped contemporary cohort of CS patients. Methods and results Consecutive CS patients seen at one institution were retrospectively enrolled after undergoing laboratory testing, electrocardiogram, echocardiography, cardiac magnetic resonance (CMR) imaging and $^{18}$F‐flourodeoxyglucose positron emission tomography (FDG‐PET) at baseline. The composite endpoint consisted of all‐cause mortality, aborted sudden cardiac death, major ventricular arrhythmic events, heart failure hospitalization and heart transplantation. A total of 319 CS patients were studied (67% male, 55.4 ± 12 years). During a median follow‐up of 2.2 years (range: 1 month–11 years), 8% of patients died, while 33% reached the composite endpoint. The annualized mortality rate was 2.7% and the 5‐ and 10‐year mortality rates were 6.2% and 7.5%, respectively. Multivariate analysis showed serum brain natriuretic peptide (BNP) levels (hazard ratio [HR] 2.41, 95% confidence interval [CI] 1.34–4.31, p = 0.003), CMR left ventricular ejection fraction (LVEF) (HR 0.96, 95% CI 0.94–0.98, p < 0.0001) and maximum standardized uptake value of FDG‐PET (HR 1.11, 95% CI 1.04–1.19, p = 0.001) to be independent predictors of outcome. These findings remained robust for different patient subgroups. Conclusion Cardiac sarcoidosis is associated with significant morbidity and mortality, particularly in those with cardiac involvement as the first manifestation. Higher BNP levels, lower LVEF and more active myocardial inflammation were independent predictors of outcomes.

Published
2023

8. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.

Author

Alaggio, Rita, Alaggio, Rita, Amador, Catalina, Anagnostopoulos, Ioannis, Attygalle, Ayoma D, Araujo, Iguaracyra Barreto de Oliveira, Berti, Emilio, Bhagat, Govind, Borges, Anita Maria, Boyer, Daniel, Calaminici, Mariarita, Chadburn, Amy, Chan, John KC, Cheuk, Wah, Chng, Wee-Joo, Choi, John K, Chuang, Shih-Sung, Coupland, Sarah E, Czader, Magdalena, Dave, Sandeep S, de Jong, Daphne, Du, Ming-Qing, Elenitoba-Johnson, Kojo S, Ferry, Judith, Geyer, Julia, Gratzinger, Dita, Guitart, Joan, Gujral, Sumeet, Harris, Marian, Harrison, Christine J, Hartmann, Sylvia, Hochhaus, Andreas, Jansen, Patty M, Karube, Kennosuke, Kempf, Werner, Khoury, Joseph, Kimura, Hiroshi, Klapper, Wolfram, Kovach, Alexandra E, Kumar, Shaji, Lazar, Alexander J, Lazzi, Stefano, Leoncini, Lorenzo, Leung, Nelson, Leventaki, Vasiliki, Li, Xiao-Qiu, Lim, Megan S, Liu, Wei-Ping, Louissaint, Abner, Marcogliese, Andrea, Medeiros, L Jeffrey, Michal, Michael, Miranda, Roberto N, Mitteldorf, Christina, Montes-Moreno, Santiago, Morice, William, Nardi, Valentina, Naresh, Kikkeri N, Natkunam, Yasodha, Ng, Siok-Bian, Oschlies, Ilske, Ott, German, Parrens, Marie, Pulitzer, Melissa, Rajkumar, S Vincent, Rawstron, Andrew C, Rech, Karen, Rosenwald, Andreas, Said, Jonathan, Sarkozy, Clémentine, Sayed, Shahin, Saygin, Caner, Schuh, Anna, Sewell, William, Siebert, Reiner, Sohani, Aliyah R, Tooze, Reuben, Traverse-Glehen, Alexandra, Vega, Francisco, Vergier, Beatrice, Wechalekar, Ashutosh D, Wood, Brent, Xerri, Luc, Xiao, Wenbin, Alaggio, Rita, Alaggio, Rita, Amador, Catalina, Anagnostopoulos, Ioannis, Attygalle, Ayoma D, Araujo, Iguaracyra Barreto de Oliveira, Berti, Emilio, Bhagat, Govind, Borges, Anita Maria, Boyer, Daniel, Calaminici, Mariarita, Chadburn, Amy, Chan, John KC, Cheuk, Wah, Chng, Wee-Joo, Choi, John K, Chuang, Shih-Sung, Coupland, Sarah E, Czader, Magdalena, Dave, Sandeep S, de Jong, Daphne, Du, Ming-Qing, Elenitoba-Johnson, Kojo S, Ferry, Judith, Geyer, Julia, Gratzinger, Dita, Guitart, Joan, Gujral, Sumeet, Harris, Marian, Harrison, Christine J, Hartmann, Sylvia, Hochhaus, Andreas, Jansen, Patty M, Karube, Kennosuke, Kempf, Werner, Khoury, Joseph, Kimura, Hiroshi, Klapper, Wolfram, Kovach, Alexandra E, Kumar, Shaji, Lazar, Alexander J, Lazzi, Stefano, Leoncini, Lorenzo, Leung, Nelson, Leventaki, Vasiliki, Li, Xiao-Qiu, Lim, Megan S, Liu, Wei-Ping, Louissaint, Abner, Marcogliese, Andrea, Medeiros, L Jeffrey, Michal, Michael, Miranda, Roberto N, Mitteldorf, Christina, Montes-Moreno, Santiago, Morice, William, Nardi, Valentina, Naresh, Kikkeri N, Natkunam, Yasodha, Ng, Siok-Bian, Oschlies, Ilske, Ott, German, Parrens, Marie, Pulitzer, Melissa, Rajkumar, S Vincent, Rawstron, Andrew C, Rech, Karen, Rosenwald, Andreas, Said, Jonathan, Sarkozy, Clémentine, Sayed, Shahin, Saygin, Caner, Schuh, Anna, Sewell, William, Siebert, Reiner, Sohani, Aliyah R, Tooze, Reuben, Traverse-Glehen, Alexandra, Vega, Francisco, Vergier, Beatrice, Wechalekar, Ashutosh D, Wood, Brent, Xerri, Luc, and Xiao, Wenbin

Abstract

We herein present an overview of the upcoming 5th edition of the World Health Organization Classification of Haematolymphoid Tumours focussing on lymphoid neoplasms. Myeloid and histiocytic neoplasms will be presented in a separate accompanying article. Besides listing the entities of the classification, we highlight and explain changes from the revised 4th edition. These include reorganization of entities by a hierarchical system as is adopted throughout the 5th edition of the WHO classification of tumours of all organ systems, modification of nomenclature for some entities, revision of diagnostic criteria or subtypes, deletion of certain entities, and introduction of new entities, as well as inclusion of tumour-like lesions, mesenchymal lesions specific to lymph node and spleen, and germline predisposition syndromes associated with the lymphoid neoplasms.

Published
2022

9. Eosinophilic Vasculitis and Arteritic Anterior Ischemic Optic Neuropathy Associated With Anti-PD-L1 Therapy

Author

Berry, EC, Mullany, S, Quinlivan, A, Craig, A, New-Tolley, J, Slattery, J, Sukumaran, S, Klebe, S, Craig, JE, Siggs, OM, Wechalekar, MD, Berry, EC, Mullany, S, Quinlivan, A, Craig, A, New-Tolley, J, Slattery, J, Sukumaran, S, Klebe, S, Craig, JE, Siggs, OM, and Wechalekar, MD

Abstract

Immune checkpoint inhibitor therapy is frequently associated with immune-related adverse events, which occasionally manifest with visual symptoms. Here, we describe a case of unilateral and sudden-onset painless vision loss in an 82-year-old man with metastatic non-small cell lung cancer receiving immunotherapy with the anti-programmed death-ligand 1 agent atezolizumab. Examination demonstrated a right-sided relative afferent pupillary defect, diffusely swollen optic disc, and delayed choroidal and retinal arterial filling on fundus fluorescein angiography, consistent with an arteritic anterior ischemic optic neuropathy. Histology of an ipsilateral temporal artery biopsy revealed a transmural eosinophilic infiltrate without granulomas, while serology revealed the presence of antineutrophil cytoplasmic antibodies. Peripheral eosinophilia was also noted, which preceded treatment by several months. This report highlights the importance of clinician awareness of immune checkpoint inhibitors and their systemic and ophthalmic complications, which rarely appear to extend to eosinophilic temporal arteritis.

Published
2022

10. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis : an open-label Phase 2 study and an adjunctive immuno-PET imaging study

Author

Wechalekar, Ashutosh, Antoni, Gunnar, Al Azzam, Wasfi, Bergstrom, Mats, Biswas, Swethajit, Chen, Chao, Cheriyan, Joseph, Cleveland, Matthew, Cookson, Louise, Galette, Paul, Janiczek, Robert L., Kwong, Raymond Y., Lukas, Mary Ann, Millns, Helen, Richards, Duncan, Schneider, Ian, Solomon, Scott D., Sörensen, Jens, Storey, James, Thompson, Douglas, van Dongen, Guus, Vugts, Danielle J., Wall, Anders, Wikström, Gerhard, Falk, Rodney H., Wechalekar, Ashutosh, Antoni, Gunnar, Al Azzam, Wasfi, Bergstrom, Mats, Biswas, Swethajit, Chen, Chao, Cheriyan, Joseph, Cleveland, Matthew, Cookson, Louise, Galette, Paul, Janiczek, Robert L., Kwong, Raymond Y., Lukas, Mary Ann, Millns, Helen, Richards, Duncan, Schneider, Ian, Solomon, Scott D., Sörensen, Jens, Storey, James, Thompson, Douglas, van Dongen, Guus, Vugts, Danielle J., Wall, Anders, Wikström, Gerhard, and Falk, Rodney H.

Abstract

Background In a Phase I study treatment with the serum amyloid P component (SAP) depleter miridesap followed by monoclonal antibody to SAP (dezamizumab) showed removal of amyloid from liver, spleen and kidney in patients with systemic amyloidosis. We report results from a Phase 2 study and concurrent immuno-positron emission tomography (PET) study assessing efficacy, pharmacodynamics, pharmacokinetics, safety and cardiac uptake (of dezamizumab) following the same intervention in patients with cardiac amyloidosis. Methods Both were uncontrolled open-label studies. After SAP depletion with miridesap, patients received <= 6 monthly doses of dezamizumab in the Phase 2 trial (n = 7), <= 2 doses of non-radiolabelled dezamizumab plus [Zr-89]Zr-dezamizumab (total mass dose of 80 mg at session 1 and 500 mg at session 2) in the immuno-PET study (n = 2). Primary endpoints of the Phase 2 study were changed from baseline to follow-up (at 8 weeks) in left ventricular mass (LVM) by cardiac magnetic resonance imaging and safety. Primary endpoint of the immuno-PET study was [Zr-89]Zr-dezamizumab cardiac uptake assessed via PET. Results Dezamizumab produced no appreciable or consistent reduction in LVM nor improvement in cardiac function in the Phase 2 study. In the immuno-PET study, measurable cardiac uptake of [Zr-89]Zr-dezamizumab, although seen in both patients, was moderate to low. Uptake was notably lower in the patient with higher LVM. Treatment-associated rash with cutaneous small-vessel vasculitis was observed in both studies. Abdominal large-vessel vasculitis after initial dezamizumab dosing (300 mg) occurred in the first patient with immunoglobulin light chain amyloidosis enrolled in the Phase 2 study. Symptom resolution was nearly complete within 24 h of intravenous methylprednisolone and dezamizumab discontinuation; abdominal computed tomography imaging showed vasculitis resolution by 8 weeks. Conclusions Unlike previous observations of visceral amyloid reduction

Published
2022
Full Text
View/download PDF

11. Artificial intelligence and the future of radiographic scoring in rheumatoid arthritis: a viewpoint

Author

Bird, A, Oakden-Rayner, L, McMaster, C, Smith, LA, Zeng, M, Wechalekar, MD, Ray, S, Proudman, S, Palmer, LJ, Bird, A, Oakden-Rayner, L, McMaster, C, Smith, LA, Zeng, M, Wechalekar, MD, Ray, S, Proudman, S, and Palmer, LJ

Abstract

Rheumatoid arthritis is an autoimmune condition that predominantly affects the synovial joints, causing joint destruction, pain, and disability. Historically, the standard for measuring the long-term efficacy of disease-modifying antirheumatic drugs has been the assessment of plain radiographs with scoring techniques that quantify joint damage. However, with significant improvements in therapy, current radiographic scoring systems may no longer be fit for purpose for the milder spectrum of disease seen today. We argue that artificial intelligence is an apt solution to further improve upon radiographic scoring, as it can readily learn to recognize subtle patterns in imaging data to not only improve efficiency, but can also increase the sensitivity to variation in mild disease. Current work in the area demonstrates the feasibility of automating scoring but is yet to take full advantage of the strengths of artificial intelligence. By fully leveraging the power of artificial intelligence, faster and more sensitive scoring could enable the ongoing development of effective treatments for patients with rheumatoid arthritis.

Published
2022

12. Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias

Author

Gevaert, Sofie A., Halvorsen, Sigrun, Sinnaeve, Peter R., Sambola, Antonia, Gulati, Geeta, Lancellotti, Patrizio, Van der Meer, Peter, Lyon, Alexander R., Farmakis, Dimitrios, Lee, Geraldine, Boriani, Giuseppe, Wechalekar, Ashutosh, Okines, Alicia, Asteggiano, Riccardo, Combes, Alain, Pfister, Roman, Bergler-Klein, Jutta, Lettino, Maddalena, Gevaert, Sofie A., Halvorsen, Sigrun, Sinnaeve, Peter R., Sambola, Antonia, Gulati, Geeta, Lancellotti, Patrizio, Van der Meer, Peter, Lyon, Alexander R., Farmakis, Dimitrios, Lee, Geraldine, Boriani, Giuseppe, Wechalekar, Ashutosh, Okines, Alicia, Asteggiano, Riccardo, Combes, Alain, Pfister, Roman, Bergler-Klein, Jutta, and Lettino, Maddalena

Abstract

Advances in treatment, common cardiovascular (CV) risk factors and the ageing of the population have led to an increasing number of cancer patients presenting with acute CV diseases. These events may be related to cancer itself or cancer treatment. Acute cardiac care specialists must be aware of these acute CV complications and be able to manage them. This may require an individualized and multidisciplinary approach. The management of acute coronary syndromes and acute pericardial diseases in cancer patients was covered in part 1 of a clinical consensus document. This second part focusses on acute heart failure, acute myocardial diseases, venous thromboembolic diseases and acute arrhythmias.

Published
2022

13. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Minnema, Monique C, Dispenzieri, Angela, Merlini, Giampaolo, Comenzo, Raymond L, Kastritis, Efstathios, Wechalekar, Ashutosh D, Grogan, Martha, Witteles, Ronald, Ruberg, Frederick L, Maurer, Mathew S, Tran, NamPhuong, Qin, Xiang, Vasey, Sandra Y, Weiss, Brendan M, Vermeulen, Jessica, Jaccard, Arnaud, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Minnema, Monique C, Dispenzieri, Angela, Merlini, Giampaolo, Comenzo, Raymond L, Kastritis, Efstathios, Wechalekar, Ashutosh D, Grogan, Martha, Witteles, Ronald, Ruberg, Frederick L, Maurer, Mathew S, Tran, NamPhuong, Qin, Xiang, Vasey, Sandra Y, Weiss, Brendan M, Vermeulen, Jessica, and Jaccard, Arnaud

Published
2022

14. IgM monoclonal gammopathies of clinical significance: diagnosis and management

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Khwaja, Jahanzaib, D'Sa, Shirley, Minnema, Monique C, Kersten, Marie José, Wechalekar, Ashutosh, Vos, Josephine M, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Khwaja, Jahanzaib, D'Sa, Shirley, Minnema, Monique C, Kersten, Marie José, Wechalekar, Ashutosh, and Vos, Josephine M

Published
2022

15. Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: results from the ANDROMEDA study

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Sanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C, Jaccard, Arnaud, Lee, Hans C, Gibbs, Simon, Mollee, Peter, Venner, Christopher, Lu, Jin, Schönland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W, Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S, Fastenau, John, Tran, Nam Phuong, Qin, Xiang, Vasey, Sandra Y, Weiss, Brendan M, Vermeulen, Jessica, Ho, Kai Fai, Merlini, Giampaolo, Comenzo, Raymond L, Kastritis, Efstathios, Wechalekar, Ashutosh D, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Sanchorawala, Vaishali, Palladini, Giovanni, Minnema, Monique C, Jaccard, Arnaud, Lee, Hans C, Gibbs, Simon, Mollee, Peter, Venner, Christopher, Lu, Jin, Schönland, Stefan, Gatt, Moshe, Suzuki, Kenshi, Kim, Kihyun, Cibeira, M Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W, Rosenzweig, Michael, Bumma, Naresh, Chauveau, Dominique, Gries, Katharine S, Fastenau, John, Tran, Nam Phuong, Qin, Xiang, Vasey, Sandra Y, Weiss, Brendan M, Vermeulen, Jessica, Ho, Kai Fai, Merlini, Giampaolo, Comenzo, Raymond L, Kastritis, Efstathios, and Wechalekar, Ashutosh D

Published
2022

16. Quantitative label-free characterisation and discrimination of osteoarthritis and rheumatoid arthritis based on hyperspectral autofluorescence features

Author

Mahbub, SB, Campbell, JM, Lees, FJ, Guller, A, Gosnell, ME, Anwer, A, Crotti, T, Wechalekar, MD, Hutchinson, MR, Goldys, E, Mahbub, SB, Campbell, JM, Lees, FJ, Guller, A, Gosnell, ME, Anwer, A, Crotti, T, Wechalekar, MD, Hutchinson, MR, and Goldys, E

Abstract

Pain is currently assessed using subjective measurements, often not aligning with clinical symptoms. Therefore, objective pain level assessments, using minimally-invasive and molecular methods, are needed to assess disease activity and response to treatment in osteoarthritis and rheumatoid arthritis. We report sophisticated quantitative biochemical “signatures” from the label-free hyperspectral imaging (HSI) of cartilage tissue for the characterization of molecular composition, structure and functional status. Further study on sinuvium tissue provides evidence that HSI could be used as a novel technique to delineate disease state. Additionally, HSI could be used to objectively separate individuals based on pain severity providing molecular correlates of pain

Published
2021

17. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis

Author

Palladini, Giovanni, Schoenland, Stefan O., Sanchorawala, Vaishali, Kumar, Shaji, Wechalekar, Ashutosh, Hegenbart, Ute, Milani, Paolo, Ando, Yukio, Westermark, Per, Dispenzieri, Angela, Merlini, Giampaolo, Palladini, Giovanni, Schoenland, Stefan O., Sanchorawala, Vaishali, Kumar, Shaji, Wechalekar, Ashutosh, Hegenbart, Ute, Milani, Paolo, Ando, Yukio, Westermark, Per, Dispenzieri, Angela, and Merlini, Giampaolo

Published
2021
Full Text
View/download PDF

18. Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis

Author

International Myeloma Foundation, Fondazione Cariplo, Cancer Research UK, Fundación Científica Asociación Española Contra el Cáncer, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Palladini, Giovanni, Paiva, Bruno, Wechalekar, Ashutosh, Massa, Margherita, Milani, Paolo, Lasa, Marta, Ravichandran, Sriram, Krsnik, Isabel, Basset, Marco, Burgos, Leire, Nuvolone, Mario, Lécumberri, Ramon, Foli, Andrea, Puig, Noemi, Sesta, Melania Antonietta, Bozzola, Margherita, Cascino, Pasquale, Nevone, Alice, Ripepi, Jessica, Berti, Pierpaolo, Casarini, Simona, Annibali, Ombretta, Orfao, Alberto, San-Miguel, Jesús, Merlini, Giampolo, International Myeloma Foundation, Fondazione Cariplo, Cancer Research UK, Fundación Científica Asociación Española Contra el Cáncer, Associazione Italiana per la Ricerca sul Cancro, Ministero della Salute, Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Palladini, Giovanni, Paiva, Bruno, Wechalekar, Ashutosh, Massa, Margherita, Milani, Paolo, Lasa, Marta, Ravichandran, Sriram, Krsnik, Isabel, Basset, Marco, Burgos, Leire, Nuvolone, Mario, Lécumberri, Ramon, Foli, Andrea, Puig, Noemi, Sesta, Melania Antonietta, Bozzola, Margherita, Cascino, Pasquale, Nevone, Alice, Ripepi, Jessica, Berti, Pierpaolo, Casarini, Simona, Annibali, Ombretta, Orfao, Alberto, San-Miguel, Jesús, and Merlini, Giampolo

Abstract

Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) and restore organ function. However, even complete hematologic response (CR), defined as negative serum and urine immunofixation and normalized free LC ratio, does not always translate into organ response. Next-generation flow (NGF) cytometry is used to detect minimal residual disease (MRD) in multiple myeloma. We evaluated MRD by NGF in 92 AL amyloidosis patients in CR. Fifty-four percent had persistent MRD (median 0.03% abnormal plasma cells). There were no differences in baseline clinical variables in patients with or without detectable MRD. Undetectable MRD was associated with higher rates of renal (90% vs 62%, p = 0.006) and cardiac response (95% vs 75%, p = 0.023). Hematologic progression was more frequent in MRD positive (0 vs 25% at 1 year, p = 0.001). Altogether, NGF can detect MRD in approximately half the AL amyloidosis patients in CR, and persistent MRD can explain persistent organ dysfunction. Thus, this study supports testing MRD in CR patients, especially if not accompanied by organ response. In case MRD persists, further treatment could be considered, carefully balancing residual organ damage, patient frailty, and possible toxicity.

Published
2021

19. Eight novel loci implicate shared genetic etiology in multiple myeloma, AL amyloidosis, and monoclonal gammopathy of unknown significance

Author

Chattopadhyay, Subhayan, Thomsen, Hauke, Weinhold, Niels, Meziane, Iman, Huhn, Stefanie, da Silva Filho, Miguel Inacio, Vodicka, Pavel, Vodickova, Ludmila, Hoffmann, Per, Nöthen, Markus M, Jöckel, Karl-Heinz, Schmidt, Börge, Landi, Stefano, Hajek, Roman, Hallmans, Göran, Pettersson-Kymmer, Ulrika, Ohlsson, Claes, Milani, Paolo, Merlini, Giampaolo, Rowcieno, Dorota, Hawkins, Philip, Hegenbart, Ute, Palladini, Giovanni, Wechalekar, Ashutosh, Schönland, Stefan O, Houlston, Richard, Goldschmidt, Hartmut, Hemminki, Kari, Försti, Asta, Chattopadhyay, Subhayan, Thomsen, Hauke, Weinhold, Niels, Meziane, Iman, Huhn, Stefanie, da Silva Filho, Miguel Inacio, Vodicka, Pavel, Vodickova, Ludmila, Hoffmann, Per, Nöthen, Markus M, Jöckel, Karl-Heinz, Schmidt, Börge, Landi, Stefano, Hajek, Roman, Hallmans, Göran, Pettersson-Kymmer, Ulrika, Ohlsson, Claes, Milani, Paolo, Merlini, Giampaolo, Rowcieno, Dorota, Hawkins, Philip, Hegenbart, Ute, Palladini, Giovanni, Wechalekar, Ashutosh, Schönland, Stefan O, Houlston, Richard, Goldschmidt, Hartmut, Hemminki, Kari, and Försti, Asta

Published
2020
Full Text
View/download PDF

20. Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group

Author

Sethi, S., Nast, C.C., D'Agati, V.D., Fervenza, F.C., Glassock, R.J., Stokes, M.B., Vriese, A.S. de, Appel, G.B., Chang, A., Cosio, F., Hernandez, L. Herrera, Markowitz, G.S., Kumar, S.K., Alexander, M.P., Amer, H., Murray, D., Nasr, S.H., Leung, N, Pani, A., Picken, M.M., Ravindran, A., Roccatello, D., Ronco, P., Royal, V., Smith, K.D., Wechalekar, A.D., Wetzels, J., Zand, L., Zhang, P., Haas, M. de, Sethi, S., Nast, C.C., D'Agati, V.D., Fervenza, F.C., Glassock, R.J., Stokes, M.B., Vriese, A.S. de, Appel, G.B., Chang, A., Cosio, F., Hernandez, L. Herrera, Markowitz, G.S., Kumar, S.K., Alexander, M.P., Amer, H., Murray, D., Nasr, S.H., Leung, N, Pani, A., Picken, M.M., Ravindran, A., Roccatello, D., Ronco, P., Royal, V., Smith, K.D., Wechalekar, A.D., Wetzels, J., Zand, L., Zhang, P., and Haas, M. de

Abstract

Contains fulltext : 225148.pdf (Publisher’s version ) (Closed access)

Published
2020

21. Modifiable Lifestyle Factors Associated With Response to Treatment in Early Rheumatoid Arthritis

Author

Brown, Z, Metcalf, R, Bednarz, J, Spargo, L, Lee, A, Hill, C, Wechalekar, M, Stavrou, C, James, M, Cleland, L, Proudman, S, Brown, Z, Metcalf, R, Bednarz, J, Spargo, L, Lee, A, Hill, C, Wechalekar, M, Stavrou, C, James, M, Cleland, L, and Proudman, S

Abstract

OBJECTIVE: We aimed to evaluate the associations between response to algorithm-directed treat-to-target conventional synthetic disease-modifying antirheumatic drug therapy and potentially modifiable lifestyle factors, including dietary fish oil supplementation, body mass index (BMI), and smoking history in a rheumatoid arthritis (RA) inception cohort. METHODS: Patients with RA with a duration of less than 12 months were reviewed every 3 to 6 weeks to adjust therapy according to disease response. All patients received advice to take fish oil supplements, and omega-3 status was measured as plasma levels of eicosapentaenoic acid (EPA). Lifestyle factors and other variables potentially prognostic for 28-joint Disease Activity Score (DAS28) remission and DAS28 low disease activity (LDA) at the 12-month visit were included in multivariable logistic regression models. RESULTS: Of 300 participants, 57.7% reached DAS28 LDA, and 43.7% were in DAS28 remission at 1 year. Increase in plasma EPA was associated with an increase in the odds of being in LDA (adjusted odds ratio [OR] = 1.27; P < 0.0001) and remission (adjusted OR = 1.21; P < 0.001). There was some evidence that the effect of BMI on LDA might be modified by smoking history. An increase in BMI was associated with a decrease in the odds of being in LDA in current and former smokers but had no impact on LDA in patients who had never smoked. There were no meaningful associations between BMI or smoking history and remission. CONCLUSION: Omega-3 status, BMI, and smoking history are potential predictors of outcome in early RA. The possibility of an effect modification by smoking on the predictive value of BMI merits further investigation.

Published
2020

22. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)

Author

Celutkiene, J, Pudil, R, Lopez-Fernandez, T, Grapsa, J, Nihoyannopoulos, P, Bergler-Klein, J, Cohen-Solal, A, Farmakis, D, Tocchetti, CG, von Haehling, S, Barberis, V, Flachskampf, FA, Ceponiene, I, Haegler-Laube, E, Suter, T, Lapinskas, T, Prasad, S, de Boer, RA, Wechalekar, K, Anker, MS, Iakobishvili, Z, Bucciarelli-Ducci, C, Schulz-Menger, J, Cosyns, B, Gaemperli, O, Belenkov, Y, Hulot, J-S, Galderisi, M, Lancellotti, P, Bax, J, Marwick, TH, Chioncel, O, Jaarsma, T, Mullens, W, Piepoli, M, Thum, T, Heymans, S, Mueller, C, Moura, B, Ruschitzka, F, Zamorano, JL, Rosano, G, Coats, AJS, Asteggiano, R, Seferovic, P, Edvardsen, T, Lyon, AR, Celutkiene, J, Pudil, R, Lopez-Fernandez, T, Grapsa, J, Nihoyannopoulos, P, Bergler-Klein, J, Cohen-Solal, A, Farmakis, D, Tocchetti, CG, von Haehling, S, Barberis, V, Flachskampf, FA, Ceponiene, I, Haegler-Laube, E, Suter, T, Lapinskas, T, Prasad, S, de Boer, RA, Wechalekar, K, Anker, MS, Iakobishvili, Z, Bucciarelli-Ducci, C, Schulz-Menger, J, Cosyns, B, Gaemperli, O, Belenkov, Y, Hulot, J-S, Galderisi, M, Lancellotti, P, Bax, J, Marwick, TH, Chioncel, O, Jaarsma, T, Mullens, W, Piepoli, M, Thum, T, Heymans, S, Mueller, C, Moura, B, Ruschitzka, F, Zamorano, JL, Rosano, G, Coats, AJS, Asteggiano, R, Seferovic, P, Edvardsen, T, and Lyon, AR

Abstract

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.

Published
2020

23. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies : a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)

Author

Celutkiene, Jelena, Pudil, Radek, Lopez-Fernandez, Teresa, Grapsa, Julia, Nihoyannopoulos, Petros, Bergler-Klein, Jutta, Cohen-Solal, Alain, Farmakis, Dimitrios, Tocchetti, Carlo Gabriele, von Haehling, Stephan, Barberis, Vassilis, Flachskampf, Frank, Ceponiene, Indre, Haegler-Laube, Eva, Suter, Thomas, Lapinskas, Tomas, Prasad, Sanjay, de Boer, Rudolf A., Wechalekar, Kshama, Anker, Markus S., Iakobishvili, Zaza, Bucciarelli-Ducci, Chiara, Schulz-Menger, Jeanette, Cosyns, Bernard, Gaemperli, Oliver, Belenkov, Yury, Hulot, Jean-Sebastien, Galderisi, Maurizio, Lancellotti, Patrizio, Bax, Jeroen, Marwick, Thomas H., Chioncel, Ovidiu, Jaarsma, Tiny, Mullens, Wilfried, Piepoli, Massimo, Thum, Thomas, Heymans, Stephane, Mueller, Christian, Moura, Brenda, Ruschitzka, Frank, Zamorano, Jose Luis, Rosano, Giuseppe, Coats, Andrew J. S., Asteggiano, Riccardo, Seferovic, Petar, Edvardsen, Thor, Lyon, Alexander R., Celutkiene, Jelena, Pudil, Radek, Lopez-Fernandez, Teresa, Grapsa, Julia, Nihoyannopoulos, Petros, Bergler-Klein, Jutta, Cohen-Solal, Alain, Farmakis, Dimitrios, Tocchetti, Carlo Gabriele, von Haehling, Stephan, Barberis, Vassilis, Flachskampf, Frank, Ceponiene, Indre, Haegler-Laube, Eva, Suter, Thomas, Lapinskas, Tomas, Prasad, Sanjay, de Boer, Rudolf A., Wechalekar, Kshama, Anker, Markus S., Iakobishvili, Zaza, Bucciarelli-Ducci, Chiara, Schulz-Menger, Jeanette, Cosyns, Bernard, Gaemperli, Oliver, Belenkov, Yury, Hulot, Jean-Sebastien, Galderisi, Maurizio, Lancellotti, Patrizio, Bax, Jeroen, Marwick, Thomas H., Chioncel, Ovidiu, Jaarsma, Tiny, Mullens, Wilfried, Piepoli, Massimo, Thum, Thomas, Heymans, Stephane, Mueller, Christian, Moura, Brenda, Ruschitzka, Frank, Zamorano, Jose Luis, Rosano, Giuseppe, Coats, Andrew J. S., Asteggiano, Riccardo, Seferovic, Petar, Edvardsen, Thor, and Lyon, Alexander R.

Abstract

Cardiovascular (CV) imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies. This position statement examines the role of echocardiography, cardiac magnetic resonance, nuclear cardiac imaging and computed tomography in the management of cancer patients. The Imaging and Cardio-Oncology Study Groups of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) in collaboration with the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the ESC have evaluated the current evidence for the value of modern CV imaging in the cardio-oncology field. The most relevant echocardiographic parameters, including global longitudinal strain and three-dimensional ejection fraction, are proposed. The protocol for baseline pre-treatment evaluation and specific surveillance algorithms or pathways for anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor tyrosine kinase inhibitors, BCr-Abl tyrosine kinase inhibitors, proteasome inhibitors and immune checkpoint inhibitors are presented. The indications for CV imaging after completion of oncology treatment are considered. The typical consequences of radiation therapy and the possibility of their identification in the long term are also summarized. Special populations are discussed including female survivors planning pregnancy, patients with carcinoid disease, patients with cardiac tumours and patients with right heart failure. Future directions and ongoing CV imaging research in cardio-oncology are discussed.

Published
2020
Full Text
View/download PDF

24. Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis

Author

Reid, Alistair B, Wiese, Michael, McWilliams, Leah, Metcalf, Rob, Hall, Cindy, Lee, Anita, Hill, Catherine, Wechalekar, Mihir, Cleland, Les, Proudman, Susanna, Reid, Alistair B, Wiese, Michael, McWilliams, Leah, Metcalf, Rob, Hall, Cindy, Lee, Anita, Hill, Catherine, Wechalekar, Mihir, Cleland, Les, and Proudman, Susanna

Abstract

© 2019 Royal Australasian College of Physicians Aim: To Investigate the prevalence of seroconversion to ACPA after commencement of triple disease-modifying anti-rheumatic drug (DMARD) treat-to-target therapy. Background: Anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) define ‘seropositive’ rheumatoid arthritis (RA). Both predict unfavourable disease course, development of extra-articular features and treatment outcomes. We investigated the prevalence of seroconversion to ACPA after commencement of triple disease-modifying anti-rheumatic drug (DMARD) treat-to-target therapy. Methods: DMARD-naïve patients with RA according to the 1987 American College of Rheumatology criteria and disease duration of <96 weeks were enrolled. RF and ACPA levels were recorded at baseline and sequentially during triple DMARD therapy. Results: A total of 368 patients were followed for a median of 272 weeks. Of 154 patients seronegative for ACPA at>recruitment, 10 (6.5%) seroconverted at some point. Nine of these were positive for RF at baseline and baseline RF titre was predictive of seroconversion. Four (2.6%) patients remained seropositive. No patients seroconverted from negative to positive for both RF and ACPA. Median time to seroconversion for ACPA was 29 months. Conclusion: Persistent seroconversion of ACPA from negative to positive after diagnosis in patients with RA is uncommon. ACPA and RF double negative patients are highly unlikely to ever develop ACPA positivity with a risk <1%. It is therefore unlikely to be helpful or cost effective to perform serial ACPA measurements in patients with seronegative RA after commencement of a treat-to-target strategy.

Published
2020

25. Challenges in the Management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria Teresa, Blade, Joan, Dimopoulos, Meletios A, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Kastritis, Efstathios, Wechalekar, Ashutosh, Schönland, Stefan, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Minnema, Monique, Roussel, Murielle, Jaccard, Arnaud, Hegenbart, Ute, Kumar, Shaji, Cibeira, Maria Teresa, Blade, Joan, and Dimopoulos, Meletios A

Published
2020

26. Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S, Zonder, Jeffrey A, Minnema, Monique C, Wechalekar, Ashutosh D, Jaccard, Arnaud, Lee, Hans C, Bumma, Naresh, Kaufman, Jonathan L, Medvedova, Eva, Kovacsovics, Tibor J, Rosenzweig, Michael A, Sanchorawala, Vaishali, Qin, Xiang, Vasey, Sandra Y, Weiss, B, Vermeulen, Jessica, Merlini, Giampaolo, Comenzo, Raymond L, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Palladini, Giovanni, Kastritis, Efstathios, Maurer, Mathew S, Zonder, Jeffrey A, Minnema, Monique C, Wechalekar, Ashutosh D, Jaccard, Arnaud, Lee, Hans C, Bumma, Naresh, Kaufman, Jonathan L, Medvedova, Eva, Kovacsovics, Tibor J, Rosenzweig, Michael A, Sanchorawala, Vaishali, Qin, Xiang, Vasey, Sandra Y, Weiss, B, Vermeulen, Jessica, Merlini, Giampaolo, and Comenzo, Raymond L

Published
2020

27. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, and Janakiram, Murali

Published
2019

28. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, Janakiram, Murali, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Dimopoulos, Meletios A., Gay, Francesca, Schjesvold, Fredrik, Beksac, Meral, Hajek, Roman, Weisel, Katja Christina, Goldschmidt, Hartmut, Maisnar, Vladimir, Moreau, Philippe, Min, Chang Ki, Pluta, Agnieszka, Chng, Wee-Joo, Kaiser, Martin, Zweegman, Sonja, Mateos, Maria Victoria, Spencer, Andrew, Iida, Shinsuke, Morgan, Gareth, Suryanarayan, Kaveri, Teng, Zhaoyang, Skacel, Tomas, Palumbo, Antonio, Dash, Ajeeta B., Gupta, Neeraj, Labotka, Richard, Rajkumar, S. Vincent, Bar, Daniel, Basso, Alfredo, Fantl, Dorotea, He, Simon, Horvath, Neomi, Lee, Cindy, Rowlings, Phillip, Taylor, Kerry, Cochrane, Tara, Kwok, Fiona, Ramanathan, Sundreswran, Agis, Hermine, Zojer, Niklas, Kentos, Alain, Offner, Fritz, Van Droogenbroeck, Jan, Wu, Ka Lung, Maiolino, Angelo, Martinez, Gracia, Zanella, Karla, Capra, Marcelo, Araujo, Sergio, Gregora, Evzen, Pour, Ludek, Scudla, Vlastimil, Spicka, Ivan, Abildgaard, Niels, Andersen, Niels, Jensen, Bo Amdi, Helleberg, Carsten, Plesner, Torben, Salomo, Morten, Svirskaite, Asta, Delarue, Richard, Blau, Igor, Schieferdecker, Aneta, Teleanu, Veronica, Munder, Markus, Rollig, Christoph, Salwender, Han-Juergen, Fuhrmann, Stephan, Weisel, Katja, Duerig, Jan, Zeis, Matthias, Klein, Stefan, Reimer, Peter, Schmidt, Christian, Scheid, Christof, Mayer, Karin, Hoffmann, Martin, Sosada, Markus, Dimopoulos, Athanasios, Delimpasi, Sosana, Kyrtsonis, Mary-Christine, Anagnostopoulos, Achilleas, Nagy, Zsolt, Illes, Arpad, Egyed, Miklos, Borbenyi, Zita, Mikala, Gabor, Dally, Najib, Horowitz, Netanel, Gutwein, Odit, Nemets, Anatoly, Vaxman, Iuliana, Shvetz, Olga, Trestman, Svetlana, Ruchlemer, Rosa, Nagler, Arnon, Tadmor, Tamar, Rouvio, Ory, Preis, Meir, Cavo, Michele, De Rosa, Luca, Musto, Pellegrino, Cafro, Anna, Tosi, Patrizia, Offidani, Massimo, Corso, Alessandro, Rossi, Giuseppe, Liberati, Anna Marina, Bosi, Alberto, Suzuki, Kenshi, Nakaseko, Chiaki, Ishikawa, Takayuki, Matsumoto, Morio, Nagai, Hirokazu, Sunami, Kazutaka, Chou, Takaaki, Akashi, Koichi, Takezako, Naoki, Hagiwara, Shotaro, Eom, Hyeon Seok, Jo, Deog-Yeon, Kim, Jin Seok, Lee, Jae Hoon, Yoon, Sung Soo, Yoon, Dok Hyun, Kim, Kihyun, Levin, Mark-David, Vellenga, Edo, Minnema, Monique, Waage, Anders, Haukas, Einar, Grosicki, Sebastian, Pluta, Andrzej, Robak, Tadeusz, Marques, Herlander, Bergantim, Rui, Campilho, Fernando, Chng, Wee Joo, Goh, Yeow Tee, McDonald, Andrew, Rapoport, Bernado, Rivas, Miguel Angel Alvarez, de La Fuente, Felipe De Arriba, Montes, Yolanda Gonzalez, Sanchez, Jesus Martin, Rocafiguera, Albert Oriol, Rosinol, Laura, San Miguel, Jesus, de Oteyza, Jaime Perez, Encinas, Cristina, Alegre-Amor, Adrian, Lopez-Guia, Ana, Axelsson, Per, Carlson, Kristina, Stromberg, Olga, Hansson, Markus, Blimark, Cecile Hveding, Mueller, Rouven, Chen, Chih-Cheng, Liu, Ta-Chih, Huang, Shang-Yi, Wang, Po-Nan, Nakorn, Thanyaphong Na, Prayongratana, Kannadit, Unal, Ali, Goker, Hakan, Sonmez, Mehmet, Korenkova, Sybiryna, Chaidos, Aristeidis, Oakervee, Heather, Sati, Hamdi, Benjamin, Reuben, Wechalekar, Ashutosh, Garg, Mamta, Ramasamy, Karthik, Cook, Gordon, Chantry, Andrew, Jenner, Matthew, Buadi, Francis, Berryman, Robert, and Janakiram, Murali

Published
2019

29. Correction to: Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Najm, Aurélie, Le Goff, Benoît, Orr, Carl, Thurlings, Rogier, Cañete, Juan D, Humby, Frances, Alivernini, Stefano, Manzo, Antonio, Just, Søren Andreas, Romão, Vasco C, Krenn, Veit, Müller-Ladner, Ulf, Addimanda, Olga, Tas, Sander W, Stoenoiu, Maria, Meric de Bellefon, Laurent, Durez, Patrick, Strand, Vibeke, Wechalekar, Mihir D, Fonseca, Joao E, Lauwerys, Bernard, Fearon, Ursula, Veale, Douglas J, EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Najm, Aurélie, Le Goff, Benoît, Orr, Carl, Thurlings, Rogier, Cañete, Juan D, Humby, Frances, Alivernini, Stefano, Manzo, Antonio, Just, Søren Andreas, Romão, Vasco C, Krenn, Veit, Müller-Ladner, Ulf, Addimanda, Olga, Tas, Sander W, Stoenoiu, Maria, Meric de Bellefon, Laurent, Durez, Patrick, Strand, Vibeke, Wechalekar, Mihir D, Fonseca, Joao E, Lauwerys, Bernard, Fearon, Ursula, Veale, Douglas J, and EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group

Abstract

Following publication of the original article [1], the authors reported an error in the spelling of the ninth author's name.

Published
2018

30. Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups.

Author

UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Najm, Aurélie, Le Goff, Benoît, Orr, Carl, Thurlings, Rogier, Cañete, Juan D, Humby, Frances, Alivernini, Stefano, Manzo, Antonio, Just, Søren Andreas, Romão, Vasco C, Krenn, Veit, Müller-Ladner, Ulf, Addimanda, Olga, Tas, Sander W, Stoenoiu, Maria, Meric de Bellefon, Laurent, Durez, Patrick, Strand, Vibeke, Wechalekar, Mihir D, Fonseca, Joao E, Lauwerys, Bernard, Fearon, Ursula, Veale, Douglas J, EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group, UCL - SSS/IREC/RUMA - Pôle de Pathologies rhumatismales, UCL - (SLuc) Service de rhumatologie, Najm, Aurélie, Le Goff, Benoît, Orr, Carl, Thurlings, Rogier, Cañete, Juan D, Humby, Frances, Alivernini, Stefano, Manzo, Antonio, Just, Søren Andreas, Romão, Vasco C, Krenn, Veit, Müller-Ladner, Ulf, Addimanda, Olga, Tas, Sander W, Stoenoiu, Maria, Meric de Bellefon, Laurent, Durez, Patrick, Strand, Vibeke, Wechalekar, Mihir D, Fonseca, Joao E, Lauwerys, Bernard, Fearon, Ursula, Veale, Douglas J, and EULAR Synovitis Study Group and OMERACT Synovial Tissue Special Interest Group

Abstract

BACKGROUND: The aim of this global collaboration was to develop a consensual set of items for the analysis of synovial biopsies in clinical practice and translational research through the EULAR Synovitis Study Group (ESSG) and OMERACT Synovial Tissue Biopsy Group. METHODS: Participants were consulted through a modified Delphi method. Three sequential rounds occurred over 12 months. Members were sent a written questionnaire containing items divided into two parts. Items were identified and formulated based on a scoping review. The first part of the questionnaire referred to synovial biopsies in clinical practice including five subsections, and the second part to translational research with six subsections. Every participant was asked to score each item on a 5-point Likert scale. Items with a median score above 3.5 and a ≥ 70% agreement were selected for the next round. The last round was conducted orally at EULAR in June 2017. RESULTS: Twenty-seven participants from 19 centers were contacted by email. Twenty participants from 17 centers answered. Response rates for next rounds were 100%. For the first part relating to clinical practice, 20/44 items (45.5%) were selected. For the second part relating to translational research, 18/43 items (41.9%) were selected for the final set. CONCLUSIONS: We herein propose a consensual set of analysis items to be used for synovial biopsies conducted in clinical practice and translational research.

Published
2018

31. Renal Amyloidosis Associated With Five Novel Variants in the Fibrinogen A Alpha Chain Protein

Author

UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, UCL - (SLuc) Service d'anatomie pathologique, Rowczenio, Dorota, Stensland, Maria, de Souza, Gustavo A., Strøm, Erik H., Gilbertson, Janet A., Taylor, Graham, Rendell, Nigel, Minogue, Shane, Efebera, Yvonne A., Lachmann, Helen J., Wechalekar, Ashutosh D., Hawkins, Philip N., Heimdal, Ketil R., Selvig, Kristian, Lægreid, Inger K., Demoulin, Nathalie, Aydin, Selda, Gillmore, Julian D., Wien, Tale N., UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, UCL - (SLuc) Service d'anatomie pathologique, Rowczenio, Dorota, Stensland, Maria, de Souza, Gustavo A., Strøm, Erik H., Gilbertson, Janet A., Taylor, Graham, Rendell, Nigel, Minogue, Shane, Efebera, Yvonne A., Lachmann, Helen J., Wechalekar, Ashutosh D., Hawkins, Philip N., Heimdal, Ketil R., Selvig, Kristian, Lægreid, Inger K., Demoulin, Nathalie, Aydin, Selda, Gillmore, Julian D., and Wien, Tale N.

Published
2017

32. Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.

Author

UCL - (SLuc) Service d'anatomie pathologique, UCL - SSS/IREC/NEFR-Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Rowczenio, Dorota, Stensland, Maria, de Souza, Gustavo A, Strøm, Erik H, Gilbertson, Janet A, Taylor, Graham, Rendell, Nigel, Minogue, Shane, Efebera, Yvonne A, Lachmann, Helen J, Wechalekar, Ashutosh D, Hawkins, Philip N, Heimdal, Ketil R, Selvig, Kristian, Lægreid, Inger K, Demoulin, Nathalie, Aydin, Selda, Gillmore, Julian D, Wien, Tale N, UCL - (SLuc) Service d'anatomie pathologique, UCL - SSS/IREC/NEFR-Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Rowczenio, Dorota, Stensland, Maria, de Souza, Gustavo A, Strøm, Erik H, Gilbertson, Janet A, Taylor, Graham, Rendell, Nigel, Minogue, Shane, Efebera, Yvonne A, Lachmann, Helen J, Wechalekar, Ashutosh D, Hawkins, Philip N, Heimdal, Ketil R, Selvig, Kristian, Lægreid, Inger K, Demoulin, Nathalie, Aydin, Selda, Gillmore, Julian D, and Wien, Tale N

Abstract

Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain (FGA) gene, and it is the most common cause of hereditary renal amyloidosis in the UK. Patients typically present with kidney impairment and progress to end-stage renal disease over a median time of 4.6 years. Six patients presented with proteinuria, hypertension, and/or lower limb edema and underwent detailed clinical and laboratory investigations. A novel FGA gene mutation was identified in each case: 2 frameshift mutations F521Sfs*27 and G519Efs*30 and 4 single base substitutions G555F, E526K, E524K, R554H. In 5 subjects, extensive amyloid deposits were found solely within the glomeruli, which stained specifically with antibodies to fibrinogen A alpha chain, and in one of these cases, we found coexistent fibrinogen A alpha chain amyloidosis and anti-glomerular basement membrane antibody disease. One patient was diagnosed with light-chain amyloidosis after a bone marrow examination revealed a small clonal plasma cell population, and laser microdissection of the amyloid deposits followed by liquid chromatography and tandem mass spectrometry identified kappa light chain as the fibril protein. We report 6 novel mutations in the FGA gene: 5 were associated with renal fibrinogen A alpha chain amyloidosis and 1 was found to be incidental to light-chain amyloid deposits discovered in a patient with a plasma cell dyscrasia. Clinical awareness and suspicion of hereditary amyloidosis corroborated by genetic analysis and adequate typing using combined immunohistochemistry and laser microdissection and mass spectrometry is valuable to avoid misdiagnosis, especially when a family history of amyloidosis is absent.

Published
2017

33. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, Dimopoulos, Meletios A, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, and Dimopoulos, Meletios A

Published
2016

34. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

Author

MS Hematologie, Regenerative Medicine and Stem Cells, Infection & Immunity, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, Dimopoulos, Meletios A, MS Hematologie, Regenerative Medicine and Stem Cells, Infection & Immunity, Leblond, Véronique, Kastritis, Efstathios, Advani, Ranjana, Ansell, Stephen M, Buske, Christian, Castillo, Jorge J, García-Sanz, Ramón, Gertz, Morie, Kimby, Eva, Kyriakou, Charalampia, Merlini, Giampaolo, Minnema, Monique C, Morel, Pierre, Morra, Enrica, Rummel, Mathias, Wechalekar, Ashutosh, Patterson, Christopher J, Treon, Steven P, and Dimopoulos, Meletios A

Published
2016

35. Australian and New Zealand recommendations for the diagnosis and management of gout: Integrating systematic literature review and expert opinion in the 3e Initiative.

Author

Buchbinder R., Whittle S.L., Wechalekar M.D., Moi J.H.Y., Barrett C., Hill C.L., Littlejohn G., Lynch N., Major G., Taylor A.L., Graf S.W., Zochling J., Buchbinder R., Whittle S.L., Wechalekar M.D., Moi J.H.Y., Barrett C., Hill C.L., Littlejohn G., Lynch N., Major G., Taylor A.L., Graf S.W., and Zochling J.

Abstract

Aim: To develop evidence-based recommendations for the diagnosis and management of gout in Australia and New Zealand as part of the multi-national 3e Initiative. Method(s): Using a formal voting process, a panel of 78 international rheumatologists selected 10 key clinical questions pertinent to the diagnosis and management of gout. An additional question was also developed by participating Australian and New Zealand rheumatologists. Each question was investigated with a systematic literature review. MEDLINE, EMBASE, Cochrane CENTRAL and abstracts from 2010 to 2011 European League Against Rheumatism and American College of Rheumatology meetings were searched in each review. Relevant studies were independently reviewed by two individuals for data extraction and synthesis and risk of bias assessment. Using this evidence, 47 Australian and New Zealand rheumatologists developed national recommendations. For each recommendation the level of agreement was assessed and the level of evidence graded. Result(s): Eleven recommendations were produced relating to the diagnosis of gout, different aspects of the management of gout, cardiovascular and renal comorbidities and the management of asymptomatic hyperuricemia. The mean level of agreement with the recommendations was 9.1 on a 1-10 scale, with 10 representing full agreement. Conclusion(s): Eleven Australian and New Zealand recommendations on the diagnosis and management of gout were developed combining systematically reviewed evidence with local expertise, enhancing their utility in clinical practice.Copyright © 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Published
2015

36. Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations

Author

Rowczenio, Dorota M., Noor, Islam, Gillmore, Julian D., Lachmann, Helen J., Whelan, Carol, Hawkins, Philip N., Obici, Laura, Westermark, Per, Grateau, Gilles, Wechalekar, Ashutosh D., Rowczenio, Dorota M., Noor, Islam, Gillmore, Julian D., Lachmann, Helen J., Whelan, Carol, Hawkins, Philip N., Obici, Laura, Westermark, Per, Grateau, Gilles, and Wechalekar, Ashutosh D.

Abstract

Hereditary systemic amyloidosis comprises a group of rare monogenic diseases inherited in an autosomal dominant fashion. It is associated with mutations in genes encoding eight different proteins, including transthyretin, apolipoprotein AI, apolipoprotein AII, lysozyme, fibrinogen A alpha-chain, cystatin C, gelsolin and beta-2-microglobulin. With support from the EU FP6 EURAMY project we have designed an online registry of genes and mutations in hereditary amyloidosis including their associated clinical phenotypes, with a view to having a single free online portal for the collection and distribution of this information. Users can search the registry by either mutation, phenotype or authors who have published or submitted mutations. It provides a submission form for reporting newly identified mutations. We also wanted to introduce nomenclature which complies with recommendations set out by Human Genome Variation Society and HUGO Gene Nomenclature Committee for description of new and known genetic variants. We hope this registry would be a useful and convenient tool for the medical and scientific community.

Published
2014
Full Text
View/download PDF

37. Amyloidosis : diagnostic investigations, clinical categories, prognosis and management

Author

Mahmood, A. S., Hawkins, P. N., and Wechalekar, A. D.

Subjects
616.3
Abstract

BACKGROUND: Amyloidosis is a very rare disorder of protein misfolding characterised by the deposition of certain proteins in an abnormal fibrillary form within the extracellular space, which disrupts the normal structure and function of organs throughout the body. Amyloid deposition may be systemic or localised, though there have been few systematic clinical studies of the latter. Treatment depends on the respective amyloid fibril type, and comprises chemotherapy regimens derived from myeloma for the most prevalent systemic monoclonal immunoglobulin light chain (AL) type. The clinical features of systemic AL amyloidosis are protean, commonly including a variety of poorly understood coagulation abnormalities and fatigue symptoms of uncertain cause. Measurement of serum free light chains (FLC) has been a very important advance in guiding treatment of systemic AL amyloidosis. Novel treatment approaches include the serum amyloid P component (SAP) depleting drug ((R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl] pyrrolidine-2 carboxylic acid which has shown promise in a pilot study in patients with hereditary fibrinogen amyloidosis. AIMS: To compare the performance of two commercially available serum free light chain assays and study the prognostic utility of each in systemic AL amyloidosis. To investigate the underlying bleeding and coagulation abnormalities, associated prognostic implications, endothelial dysfunction and implications for the possibility of light chain toxicity. To explore the sleep disordered breathing morbidity in amyloidosis. To investigate the incidence, patient characteristics and survival outcomes in patients with localised AL amyloidosis. To explore a subgroup of localised amyloidosis: tracheobronchial and laryngeal amyloidosis from a clinical and proteomic perspective. To examine two types of treatment in systemic amyloidosis: the use of lenalidomide based chemotherapy with prior use of Thalidomide/Bortezomib treatment in systemic AL amyloidosis and CPHPC treatment. RESULTS AND CONCLUSIONS: Both FreeliteTM and N Latex assays have high sensitivity for detecting abnormal FLC in patients with systemic light chain amyloidosis, showing an excellent correlation between the assays for identifying the abnormal light chain subtype but with discordance in the absolute values. Coagulation abnormalities in systemic AL amyloidosis were frequent and included the following abnormalities: elevated concentration of fibrinogen in 42 (56.8%), elevated FVIII 67 (90.5%) and vWF Ag 67 (90.5%). Kaplan Meier estimates showed that vWF Ag (p=0.039) and FVIII (p=0.01) thresholds greater than 280IU associated with a significant survival disadvantage. A fall in the vWF Ag levels following chemotherapy in those achieving a clonal response suggests potential light chain toxicity implications. Albumin concentration lower than 25g/L correlated with coagulation factors which are prothrombotic, implying that anticoagulation may be an important consideration in newly diagnosed systemic AL. Thus these findings suggest the potential prognostic utility of vWF Ag levels and thrombotic risks associated with newly diagnosed systemic AL patients. Recurrent overnight oxygen desaturations proved to be frequent in patients with cardiac and/or soft tissue amyloidosis, although the occurrence of sleep disordered breathing (SDB) needs confirmation with formal polysomnography. Patients with poor right heart ventricular systolic function score high with SDB questionnaires, which was associated with adverse outcome in newly diagnosed cardiac AL amyloidosis. Localised AL amyloidosis is a very different disease from systemic AL amyloidosis, with a far superior prognosis. Local surgical resection is adequate in most patients with localised amyloidosis in whom treatment is needed, and radiotherapy can have a useful role in some patients whose disease cannot be controlled by local measures. Progression to systemic AL amyloidosis is extremely rare except among patients with lymph node involvement. Patients with lymph node involvement and those with isotypic specific circulating free light chains warrant closer follow up for development of systemic amyloidosis. Most patients with localised AL have excellent long term outcomes. Laryngeal and tracheobronchial amyloidosis is a subtype of localised amyloidosis, in which hoarseness and dyspnoea are the predominant symptoms, the 2 year OS 93% and 90% respectively. Proteomic analysis of amyloid dissected from biopsies showed the presence of the amyloid signature proteins, apolipoprotein A1 (in greater amounts protein) and insulin-like growth factor binding protein complex in all samples compared with patients with systemic AL or transthyretin amyloidosis. Of interest, apolipoprotein A1 has been described within the respiratory tract and insulin growth factor has been postulated to play a role in inflammation, which may be relevant with respect to the pathogenesis and effects of airways amyloidosis. Lenalidomide and dexamethasone combination treatment following prior proteasome inhibitor based therapy produced an overall haematologic response rate of 61%, including 20% complete responses. Renal responses among patients who received prolonged treatment were surprisingly frequent; twenty one out of 38 (55%) evaluable patients achieved a renal response (40% on an ITT basis) - 7 (18%) at 6 months, 7 (18%) at 12 months and an additional 7 (18%) patients at 18 months by long term follow up. This raises the possibility that immunomodulatory effects of lenalidomide therapy might enhance the otherwise slow natural regression of amyloid deposits. CPHPC depletes circulating Serum amyloid P (SAP) component as a treatment for systemic amyloidosis.1 Our study of 10 patients suggested a significant reduction in the natural progression of renal decline and renal survival along with an excellent safety profile; this was supported by our QoL assessments using SFv36 questionnaires. The work in this thesis has thus contributed to improved characterisation and clinical management of various types of amyloidosis, and has identified several avenues of therapy that merit further investigation in larger populations and randomised clinical trials.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results